XML 16 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Cash flows from operating activities:              
Net loss $ (29,579,076) $ (29,288,867) $ (6,639,125) $ (32,350,828) $ (58,867,943) $ (38,989,953)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation         1,863,225 1,841,084  
Amortization of intangible assets 267,000   312,000   533,126 716,458  
Change in value of common stock warrants         0 (132,130)  
Stock-based compensation         6,787,991 6,164,958  
Non-cash interest expense 2,194,783   0   2,851,031 0  
Amortization of premiums on investments         1,962 71,559  
Loss (gain) on short-term investments         (93,273) 373,822  
Loss (gain) on equity investment in affiliated entities 173,212   2,092,608   923,315 (287,815)  
Non-cash lease expense         412,533 0  
Tax benefit from other unrealized gains on short-term investments         (335,228) 0  
Changes in operating assets and liabilities:              
Accounts receivable         3,186,131 4,290,243  
Accounts receivable from affiliated entities         (258,353) (473,834)  
Prepaid expenses and other current assets         (902,772) 815,825  
Prepaid expenses and other current assets from affiliated entities         20,059 58,710  
Other assets         (183,091) (85,022)  
Accounts payable and accrued expenses         (9,187,074) (9,443,933)  
Accrued clinical trial expenses         (1,033,367) 1,747,980  
Accounts payable and accrued expenses due to affiliated entities         (324,224) (326,242)  
Deferred revenue         (137,046) (453,688)  
Deferred revenue from affiliated entities         62,500 (118,985)  
Operating lease right-of-use assets and liabilities, net         (786,079) (177,096)  
Deferred grant funding         (1,695,191) 2,620,985  
Deferred grant funding from affiliated entities         817,125 188,800  
Other liabilities         (34,688) 0  
Net cash used in operating activities         (56,379,331) (31,598,274)  
Cash flows from investing activities:              
Purchases of investments         (73,698,391) (31,318,982)  
Maturities of investments         46,688,689 53,753,066  
Purchases of capital assets         (739,808) (1,614,767)  
Net cash (used in) provided by investing activities         (27,749,510) 20,819,317  
Cash flows from financing activities:              
Proceeds from issuance of convertible senior notes         75,658,953 0  
Proceeds from issuance of common stock, net of issuance costs         2,296,316 1,973,401  
Taxes paid related to net share settlement of equity awards, net of proceeds from stock option exercises         (800,656) 104,620  
Acquisition of non-controlling interest         3,016,538 0  
Net cash provided by financing activities         80,171,151 2,078,021  
Decrease in cash and cash equivalents         (3,957,690) (8,700,936)  
Cash and cash equivalents, beginning of period   $ 23,693,633   $ 23,786,579 23,693,633 23,786,579 $ 23,786,579
Cash and cash equivalents, end of period $ 19,735,943   $ 15,085,643   19,735,943 15,085,643 $ 23,693,633
Supplemental disclosure of non-cash activities              
Amounts accrued for purchases of property and equipment         $ 0 $ 29,211